Metagenomi, Inc.
MGX
$1.86
-$0.05-2.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.77M | 45.26M | 52.30M | 55.08M | 55.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.77M | 45.26M | 52.30M | 55.08M | 55.93M |
| Cost of Revenue | 97.07M | 102.88M | 109.18M | 110.77M | 111.35M |
| Gross Profit | -63.30M | -57.62M | -56.88M | -55.69M | -55.42M |
| SG&A Expenses | 28.51M | 30.07M | 32.02M | 32.78M | 33.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.58M | 132.95M | 141.20M | 143.55M | 144.42M |
| Operating Income | -91.81M | -87.69M | -88.90M | -88.47M | -88.49M |
| Income Before Tax | -90.29M | -83.36M | -83.57M | -75.53M | -73.27M |
| Income Tax Expenses | -3.17M | -5.42M | -5.51M | -1.58M | 1.73M |
| Earnings from Continuing Operations | -87.12 | -77.95 | -78.06 | -73.95 | -75.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.12M | -77.95M | -78.06M | -73.95M | -75.00M |
| EBIT | -91.81M | -87.69M | -88.90M | -88.47M | -88.49M |
| EBITDA | -86.30M | -82.20M | -83.49M | -83.33M | -83.55M |
| EPS Basic | -2.35 | -2.11 | -2.62 | -7.66 | -12.97 |
| Normalized Basic EPS | -1.35 | -1.25 | -1.58 | -4.33 | -7.42 |
| EPS Diluted | -2.35 | -2.11 | -2.62 | -7.66 | -12.97 |
| Normalized Diluted EPS | -1.35 | -1.25 | -1.58 | -4.33 | -7.42 |
| Average Basic Shares Outstanding | 148.25M | 147.72M | 131.84M | 97.93M | 64.57M |
| Average Diluted Shares Outstanding | 148.25M | 147.72M | 131.84M | 97.93M | 64.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |